BioCentury
ARTICLE | Company News

Antigen Express Inc. other research news

April 9, 2001 7:00 AM UTC

Antigen received a $192,000 Phase I SBIR grant from the National Cancer Institute to develop a prostate cancer vaccine based on the induction of MHC class II and suppression of Ii protein expression i...